MedTrace Logo

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

NCT00618605 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-11-01

No results posted yet for this study

Summary

Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response. The purpose of this study is to determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfected adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

Ad26.ENVA.01 HIV-1 vaccine

Recombinant adenovirus serotype 26 HIV-1 vaccine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Lindsey Baden, MD · Brigham and Women's Hospital

  • Dan Barouch, MD, PhD · Beth Israel Deaconess Medical Center

  • Raphael Dolin, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-07-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618605 on ClinicalTrials.gov